The activation of DCs (CD86 +, CD80+, CD83+, HLA-DR+), CTLs (CD3+CD8+) and NKT (CD3+CD56+) cells were all increased in 6B11-OCIK of the three patients during in vitro culture and showed good killing effect on ovarian cancer cells. This evidence concerns the gene CD86 and ovarian cancer.